RecruitingNot ApplicableNCT06498063

The Underlying Mechanisms Regarding the Effect of Glucagon on the Kidneys Will be Investigated in Healthy Males.

Renal Extraction of Glucagon and Renal Effects of Glucagon


Sponsor

Ali Asmar

Enrollment

10 participants

Start Date

Feb 20, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this crossover study is to investigate to what extend glucagon affects the kidneys. The main questions it aims to answer are: Does glucagon regulate kidney function through extraction in the kidney in addition to glomerular filtration? Does glucagon regulate kidney function by increasing renal plasma flow and glomerular filtration rate? Does glucagon regulate kidney function by increasing renal salt excretion?


Eligibility

Sex: MALEMin Age: 20 YearsMax Age: 60 Years

Inclusion Criteria4

  • Age: 20-60 years
  • Normal health ascertained through questioning and medical examination
  • Normal values for blood concentrations of fasting plasma glucose, fasting plasma total cholesterol, fasting triglycerides, HDL, LDL, creatinine, liver function, and electrolytes
  • Informed consent

Exclusion Criteria7

  • Immunosuppressive treatment in the preceding 12 months
  • Alcohol abuse
  • Medical treatment with oral glucocorticoids, dipeptidyl peptidase-4 (DPP-4) inhibitors, or GLP-1 receptor agonists, which, in the opinion of the investigator, may interfere with glucose metabolism
  • Use of lithium
  • Medical treatment that affects insulin secretion or cardiovascular performance measures
  • Liver disease (ALT > 2x normal value)
  • Renal impairment (se-creatinine > 130 μM and/or albuminuria)

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERGlucagon

Glucagon infusion of 5 ng·kg-1·min-1 from 0-60 minutes and 10 ng·kg-1 ·min-1 from 60-120 minutes.

OTHERPlacebo

Placebo (0.9% NaCl).

OTHERGlucagon and exendin 9-39

Glucagon (infusion of 5 ng·kg-1·min-1 from 0-60 minutes) and glucagon (infusion of 10 ng·kg-1 ·min-1 from 60-120 minutes) + a GLP-1R antagonist, exendin 9-39 (900 pmol·kg-1·min-1 from -30-120 minutes).


Locations(1)

Physiological laboratory, Bispebjerg Hospital, Research Unit, Clinical Physiology / Nuclear Medicine Department

Copenhagen, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06498063


Related Trials